ADCT
ADC Therapeutics S.A.
NYSE · Healthcare · Biotechnology · CH
$1.34
+1.14%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 2.02x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- -0.75x
- Price / sales
- 2.16x
- Price / cash flow
- -1.67x
Enterprise value
- Enterprise value
- $368.4M
- EV / sales
- 4.68x
- EV / EBITDA
- -4.21x
- EV / EBIT
- -3.72x
- Market cap
- $170.4M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026